Dermatologic symptoms associated with the multikinase inhibitor sorafenibROBERT, Caroline; MATEUS, Christina; SPATZ, Alain et al.Journal of the American Academy of Dermatology. 2009, Vol 60, Num 2, pp 299-305, issn 0190-9622, 7 p.Article

A New Spectrum of Skin Toxic Effects Associated With the Multikinase Inhibitor VandetanibGIACCHERO, Damien; RAMACCIOTTI, Constanza; ROBERT, Caroline et al.Archives of dermatology (1960). 2012, Vol 148, Num 12, pp 1418-1420, issn 0003-987X, 3 p.Article

First-in-Human Phase I Trial of Two Schedules of OSI-930, a Novel Multikinase Inhibitor, Incorporating Translational Proof-of-Mechanism StudiesYAP, Timothy A; ARKENAU, Hendrik-Tobias; LEACH, Martin O et al.Clinical cancer research (Print). 2013, Vol 19, Num 4, pp 909-919, issn 1078-0432, 11 p.Article

Sorafenib: Where Do We Go from Here?SIEGEL, Abby B; OLSEN, Sonja K; MAGUN, Arthur et al.Hepatology (Baltimore, Md.). 2010, Vol 52, Num 1, pp 360-369, issn 0270-9139, 10 p.Article

Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. CommentaryJOENSUU, Heikki; CHU, Tammy F; DESAI, Jayesh et al.Lancet (British edition). 2007, Vol 370, Num 9604, issn 0140-6736, 1978-1980, 2011-2019 [12 p.]Article

Dasatinib enhances megakaryocyte differentiation but inhibits platelet formationMAZHARIAN, Alexandra; GHEVAERT, Cedric; LIN ZHANG et al.Blood. 2011, Vol 117, Num 19, pp 5198-5206, issn 0006-4971, 9 p.Article

Augmentation of Radiation Response by Motesanib, a Multikinase Inhibitor that Targets Vascular Endothelial Growth Factor ReceptorsKRUSER, Tim J; WHEELER, Deric L; ARMSTRONG, Eric A et al.Clinical cancer research (Print). 2010, Vol 16, Num 14, pp 3639-3647, issn 1078-0432, 9 p.Article

Metabolism and Disposition of Dasatinib after Oral Administration to HumansCHRISTOPHER, Lisa J; DONGHUI CUI; GALBRAITH, Susan et al.Drug metabolism and disposition. 2008, Vol 36, Num 7, pp 1357-1364, issn 0090-9556, 8 p.Article

Profound Inhibition of Antigen-SpecificT-Cell Effector Functions by DasatinibWEICHSEL, Ralf; DIX, Carolin; EINSELE, Hermann et al.Clinical cancer research. 2008, Vol 14, Num 8, pp 2484-2491, issn 1078-0432, 8 p.Article

Sorafenib use while waiting for liver transplant: We still need to waitFINN, Richard S.Journal of hepatology. 2012, Vol 56, Num 3, pp 723-725, issn 0168-8278, 3 p.Article

Drug Therapy: SorafenibFINN, Richard S.Hepatology (Baltimore, Md.). 2010, Vol 51, Num 5, pp 1843-1849, issn 0270-9139, 7 p.Article

Dasatinib is a potent inhibitor of tumour-associated macrophages, osteoclasts and the FMS receptorBROWNLOW, N; MOL, C; HAYFORD, C et al.Leukemia. 2009, Vol 23, Num 3, pp 590-594, issn 0887-6924, 5 p.Article

Regorafenib: carving a niche in the crowded therapeutic landscapeSIROHI, Bhawna; DEEPA SUSAN PHILIP; SHRIKHANDE, Shailesh V et al.Expert review of anticancer therapy. 2013, Vol 13, Num 4, pp 385-393, issn 1473-7140, 9 p.Article

Dasatinib inhibits proinflammatory functions of mature human neutrophilsFUTOSI, Krisztina; NEMETH, Tamas; PICK, Robert et al.Blood. 2012, Vol 119, Num 21, pp 4981-4991, issn 0006-4971, 11 p.Article

Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinibLEE, W. J; LEE, J. L; CHANG, S. E et al.British journal of dermatology (1951). 2009, Vol 161, Num 5, pp 1045-1051, issn 0007-0963, 7 p.Article

Subacute cutaneous lupus erythematosus induced by the new multikinase inhibitor pazopanibCASADO-VERRIER, B; PEREZ-SANTOS, S; DELGADO-MUCIENTES, C et al.British journal of dermatology (1951). 2014, Vol 171, Num 6, pp 1559-1561, issn 0007-0963, 3 p.Article

Targeted Inhibition of Src Kinase with Dasatinib Blocks Thyroid Cancer Growth and MetastasisCHAN, Christine M; XIA JING; PIKE, Laura A et al.Clinical cancer research (Print). 2012, Vol 18, Num 13, pp 3580-3591, issn 1078-0432, 12 p.Article

Lysosomal Sequestration of Sunitinib: A Novel Mechanism of Drug ResistanceGOTINK, Kristy J; BROXTERMAN, Henk J; GRIFFIOEN, Arjan W et al.Clinical cancer research (Print). 2011, Vol 17, Num 23, pp 7337-7346, issn 1078-0432, 10 p.Article

Sorafenib augments cytotoxic effect of S-1 in vitro and in vivo through TS suppressionTAKEUCHI, Ario; SHIOTA, Masaki; TATSUGAMI, Katsunori et al.Cancer chemotherapy and pharmacology. 2011, Vol 68, Num 6, pp 1557-1564, issn 0344-5704, 8 p.Article

Lck is a key target of imatinib and dasatinib in T-cell activationLEE, K. C; OUWEHAND, I; GIANNINI, A. L et al.Leukemia. 2010, Vol 24, Num 4, pp 896-900, issn 0887-6924, 5 p.Article

Kutane Nebenwirkungen der Multikinaseinhibitoren Sorafenib und Sunitinib : Neue kutane Arzneimittelnebenwirkunger = Cutaneous side effects of the multikinase inhibitors sorafenib and sunitinib : New cutaneous side effects of drugsWOLLENBERG, A; STAEHLER, M; EAMES, T et al.Der Hautarzt. 2010, Vol 61, Num 8, pp 662-667, issn 0017-8470, 6 p.Article

Dasatinib Inhibits the Growth of Molecularly Heterogeneous Myeloid LeukemiasGUERROUAHEN, Bella S; FUTAMI, Muneyoshi; KORNBLAU, Steven M et al.Clinical cancer research (Print). 2010, Vol 16, Num 4, pp 1149-1158, issn 1078-0432, 10 p.Article

Enhanced Genetic Instability and Dasatinib Sensitivity in Mammary Tumor Cells Lacking NEDD9SINGH, Mahendra K; IZUMCHENKO, Eugene; KLEIN-SZANTO, Andres J et al.Cancer research (Chicago, Ill.). 2010, Vol 70, Num 21, pp 8907-8916, issn 0008-5472, 10 p.Article

Hyperkeratotic eruption, hand-foot skin reaction, facial erythema, and stomatitis secondary to multi-targeted kinase inhibitor sorafenibSAHAI, Seema; SWICK, Brian L.International journal of dermatology. 2010, Vol 49, Num 10, pp 1203-1206, issn 0011-9059, 4 p.Article

Inhibition of choroidal neovascularisation in mice by systemic administration of the multikinase inhibitor, sorafenibCHUNG, E. J; YOO, S; LIM, H. J et al.British journal of ophthalmology. 2009, Vol 93, Num 7, pp 958-963, issn 0007-1161, 6 p.Article